Last reviewed · How we verify
CSL Limited Influenza Virus Vaccine
CSL Limited Influenza Virus Vaccine is a inactivated influenza vaccine Biologic drug developed by Seqirus. It is currently FDA-approved for Seasonal influenza prevention in adults and children.
This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | CSL Limited Influenza Virus Vaccine |
|---|---|
| Sponsor | Seqirus |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated influenza virus particles or viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, B cells produce strain-specific antibodies (primarily IgG) that neutralize circulating virus, while T cells develop memory responses for rapid recall immunity. This prevents or reduces severity of influenza infection when vaccinated individuals encounter wild-type virus.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years (PHASE4)
- A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine (PHASE4)
- A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults (PHASE4)
- Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSL Limited Influenza Virus Vaccine CI brief — competitive landscape report
- CSL Limited Influenza Virus Vaccine updates RSS · CI watch RSS
- Seqirus portfolio CI
Frequently asked questions about CSL Limited Influenza Virus Vaccine
What is CSL Limited Influenza Virus Vaccine?
How does CSL Limited Influenza Virus Vaccine work?
What is CSL Limited Influenza Virus Vaccine used for?
Who makes CSL Limited Influenza Virus Vaccine?
What drug class is CSL Limited Influenza Virus Vaccine in?
What development phase is CSL Limited Influenza Virus Vaccine in?
What are the side effects of CSL Limited Influenza Virus Vaccine?
Related
- Drug class: All inactivated influenza vaccine drugs
- Manufacturer: Seqirus — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Compare: CSL Limited Influenza Virus Vaccine vs similar drugs
- Pricing: CSL Limited Influenza Virus Vaccine cost, discount & access